UNDERSTANDING HEPATITIS C VIRUS-SPECIFIC T CELL TOLERANCE
Funder
National Health and Medical Research Council
Funding Amount
$429,710.00
Summary
Most individuals who are infected with hepatitis C virus (HCV) develop a persistent infection that is lifelong and are at risk of developing serious liver disease, including liver cancer. The evidence suggests that an inadequate immune response is responsible for the inability of the patient to resolve the infection, but it is not clear which stage of the immunological cascade might be targeted. In this project, we will test the hypothesis that HCV antigen induce supressor T cells This will have ....Most individuals who are infected with hepatitis C virus (HCV) develop a persistent infection that is lifelong and are at risk of developing serious liver disease, including liver cancer. The evidence suggests that an inadequate immune response is responsible for the inability of the patient to resolve the infection, but it is not clear which stage of the immunological cascade might be targeted. In this project, we will test the hypothesis that HCV antigen induce supressor T cells This will have the effect of inhibiting the immune response and result in the outcome that we currently recognise as persistent HCV infection.Read moreRead less
Current anti-HIV therapies can't cure HIV because HIV remains silent(latent) in long-lived cells. The HIV life cycle and virus production is linked to activation of the host cell, which is regulated by dendritic cells. This grant will explore how the factors controlling T cell activation and proliferation control virus expression and latency. By understanding how latent infection is established and maintained, these studies will potentially identify new ways to eliminate HIV infection.
Prophylactic Vaccine Development For The Elimination Of Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$936,752.00
Summary
A vaccine that prevents Hepatitis C is urgently needed to prevent infection and assist with global HCV elimination targets. This project grant will advance world-leading HCV vaccine candidates that generate both humoral and cellular immunity for clinical development.
Detailed Investigation Of The Humoral Immune Response To HCV To Identify Diagnostic And Prognostic Serological Markers
Funder
National Health and Medical Research Council
Funding Amount
$387,466.00
Summary
The prevalence of Hepatitis C in Australia has been estimated at 242 000 people with 80% of infections acquired as a result of infection drug use. The currently available assays can be used to reliably determine the prevalence of Hepatitis C infection but provide no information regarding the incidence of infection. By thoroughly investigating the immune response generated by individuals infected with Hepatitis C we intend to identify interactions which can be used to differientiate between the d ....The prevalence of Hepatitis C in Australia has been estimated at 242 000 people with 80% of infections acquired as a result of infection drug use. The currently available assays can be used to reliably determine the prevalence of Hepatitis C infection but provide no information regarding the incidence of infection. By thoroughly investigating the immune response generated by individuals infected with Hepatitis C we intend to identify interactions which can be used to differientiate between the different stages of infection. The expected outcomes of this study include the identification of a marker of recent Hepatitis C infection. This will permit accurate epidemiological monitoring of Hepatitis C, better design of programs to control the spread, trace outbreaks and manage treatment programs. The identification of a marker capable of predicting the clinical outcome of infection would be invaluable to clinicians, because following acute infection with Hepatitis C, 20 to 30% of individuals will resolve their infection without the need for therapeutic intervention. The information obtained in this study will also lead to a better interpretation of diagnostic laboratory findings, improving our ability to provide clear and accurate reports to blood donors and consequently enhance the Australian blood supply in terms of safety and donor retention.Read moreRead less
Mechanisms Of Immune Modulation By Varicella Zoster Virus During Cutaneous Infections
Funder
National Health and Medical Research Council
Funding Amount
$570,446.00
Summary
Varicella zoster virus (VZV) is a herpesvirus which infects up to 90% of the population. VZV causes two skin diseases: chicken pox (varicella) predominantly in childhood and shingles (herpes zoster) in middle to old age people. Whilst VZV usually causes relatively mild disease in healthy individuals, VZV still causes significant morbidity in children and adults. VZV causes life-threatening disease in immunocompromised individuals such as patients who are elderly or have HIV disease. Shingles aff ....Varicella zoster virus (VZV) is a herpesvirus which infects up to 90% of the population. VZV causes two skin diseases: chicken pox (varicella) predominantly in childhood and shingles (herpes zoster) in middle to old age people. Whilst VZV usually causes relatively mild disease in healthy individuals, VZV still causes significant morbidity in children and adults. VZV causes life-threatening disease in immunocompromised individuals such as patients who are elderly or have HIV disease. Shingles affects many elderly individuals and a major complication is prolonged severe pain or post-herpetic neuralgia (PHN), which can be severely debilitating and often requires follow-up medical care for months or even years after the initial attack. Despite its significant impact on the community, little is known about how this virus functions and causes disease. This project aims to improve our understanding of how VZV infection of the skin affects the function of specialised skin cells in order to provide novel information for the development of therapies aimed at lessening the impact of VZV disease on the community. This project has three main components: (1) To determine what the differences are in the types of immune cells present in infected skin from chicken pox and shingles sufferers. (2) To assess the impact of VZV infection on the ability of specialised immune cells (called dendritic cells) to function properly (3) To identify which parts of the virus (called genes) code for functions that interfere with the proper function of specialised immune cells (dendritic cells)Read moreRead less
Viral Determinants Of HIV-1 Transcriptional Latency In The Central Nervous System
Funder
National Health and Medical Research Council
Funding Amount
$632,489.00
Summary
The anti-HIV drugs that are currently used to treat HIV-1 infection cannot eliminate the virus from the body, and therefore, cannot cure HIV-1 infection. The major reason why the drugs cannot provide a cure is because they cannot reach virus that hides in particular cells types referred to as "reservoirs". This study will determine how HIV-1 can take sanctuary in these reservoirs, which will be critical information for strategies that aim to cure HIV-1 infection.
Antiviral therapy for HIV infection has substantially reduced mortality but HIV can't be cured. This is because HIV causes a silent or latent infection in some cells. This grant will investigate a new class of drugs which show promise in reversing latent infection and potentially eliminating HIV from infected patients
Viral Determinants Of HIV-1 Transcriptional Latency In The Central Nervous System: Impact On Cure Strategies
Funder
National Health and Medical Research Council
Funding Amount
$847,521.00
Summary
This grant will identify the factors responsible for HIV-1 latency in the CNS, and will determine the effect of drugs aimed at reversing latency both on HIV-1 within the CNS, and also on the cells of the CNS.